Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.52 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14504548 | 0.83 | PTGS2 (0.67) | PTGS1CYP2C9PTGS2 | |
| SCHEMBL14504519 | 0.80 | PTGS2 (0.62) | PTGS1CYP2C9PTGS2 | |
| SCHEMBL6096276 | 0.80 | NPC1 (0.46) | CYP2C9MAPTPOLB | |
| SCHEMBL6097893 | 0.80 | TAAR1 (0.43) | MAPTSMN1; SMN2POLB | |
| SCHEMBL6097735 | 0.79 | PTGS1 (0.70) | PTGS1CYP2C9PTGS2PDPK1 | |
| SCHEMBL14504542 | 0.79 | PTGS2 (0.67) | PTGS1CYP2C9PTGS2SMN1; SMN2 | |
| SCHEMBL6097189 | 0.79 | PTGS2 (0.51) | PTGS1CYP2C9PTGS2PDPK1MAPT | |
| SCHEMBL14505088 | 0.78 | PTGS2 (0.65) | PTGS1CYP2C9PTGS2PDPK1 | |
| SCHEMBL14505097 | 0.78 | NR3C2 (0.58) | PTGS1CYP2C9PTGS2PDPK1 | |
| SCHEMBL6097275 | 0.77 | PTGS1 (0.70) | PTGS1CYP2C9PTGS2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | PTGS1 2/4885CYP2C9 406/4885PTGS2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.